Table 2 Prognostic factors for overall survival
From: Outcome of therapy-related myeloid neoplasms treated with azacitidine
Patients (n) | Number of responders § | Median OS (months) | p | |
|---|---|---|---|---|
Age | ||||
≤ 65 years | 24 | 10 | 21.9 | 0.85 |
> 65 years | 26 | 10 | 24.5 | |
Primary Malignancy | ||||
Hematological | 27 | 12 | 11.67 | 0.83 |
Solid | 23 | 8 | 17.97 | |
azacitidine dose | ||||
75 mg/smq/7 days | 36 | 12 | 16.7 | 0.31 |
100 mg/day 10 days | 4 | 3 | 14.2 | |
100 mg/day 5 or 7 days | 10 | 5 | 16.2 | |
WHO diagnosis | ||||
RCMD | 12 | 9 | 30.9 | |
RAEB 1/2 | 22 | 7 | 16.8 | 0.02 |
AML | 16 | 4 | 8.5 | |
Karyotype | ||||
Normal | 8 | 8 | 27.7 | |
Single or double abnormality | 9 | 3 | 11.6 | 0.66* |
Complex | 20 | 9 | 16.2 | |
Chromosome 7 abnormalities | ||||
Yes | 14 | 8 | 11.63 | 0.72 |
No | 33 | 12 | 17.96 | |
Transfusion dependence | ||||
Yes | 26 | 10 | 11.6 | 0.38 |
No | 24 | 10 | 21.9 | |
Previous Treatment | ||||
No pre-treatment | 40 | 17 | 27.7 | 0.0001 |
ESA | 4 | 2 | 16.2 | |
Hydroxyurea | 2 | 1 | 9.5 | |
Conventional Chemotherapy | 4 | 0 | 5.4 | |
HCT-CI # | ||||
0–2 | 5 | 0 | 8.8 | |
3 | 19 | 6 | 8.5 | 0.2 |
4 | 6 | 4 | 53.7 | |
>5 | 9 | 4 | 16.2 | |